For a company with relatively modest underlying growth trends, C.R.Bard (BCR)
has generated a fair bit of enthusiasm on the Street for the enhanced
growth prospects bought through M&A and the royalty stream from Gore.
Among the acquired products, investors are particularly keen on the
prospects for the Lutonix drug-coated balloon and management's comments
on the earnings call only seemed to add more confusion to already noisy
situation. Bard is not a particularly cheap stock at these levels and
the company is going to need better organic growth and clear
differentiation in drug-coated balloons to support further gains.
Read the full article here:
Noise Over DCBs Clouds An Otherwise Okay Quarter At Bard
No comments:
Post a Comment